Intensity therapeutics reports invincible-4, presurgical triple-negative breast cancer study update

A pathological complete response ("pcr") has been observed in the first patient evaluated in cohort a, where each patient receives two doses of int230-6 eight days apart, followed by the standard of care immunochemotherapy ("soc") safety looks favorable in cohort a some int230-6 patients begin to show localized skin irritation, and new patient enrollment has been paused to implement modifications to resolve the issue patients being treated with int230-6 continue to show significant necrosis after two doses of int230-6 and prior to the initiation of the soc, as shown in the photos below of a single patient's breast tumor scans shelton, conn. , sept. 10, 2025 /prnewswire/ -- intensity therapeutics, inc. ("intensity" or "the company") (nasdaq: ints), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provided an update on the invincible-4 trial.
INT Ratings Summary
INT Quant Ranking